PuraPharm Corporation Limited provided earnings guidance for the six months ended 30 June 2019. Based on the unaudited consolidated management accounts of the Group for the six months ended 30 June 2019, it is expected that the Group's revenue for the six months ended 30 June 2019 will record decrease of approximately 15%, and record a substantial net loss for the six months ended 30 June 2019 whereas the unaudited consolidated net profit recorded in the last corresponding period was HKD 13.3 million.